Anti-CD3 & EpCAM Antibody (Catumaxomab (mIgG2a-rat IgG2b))

Catumaxomab is a trifunctional bispecific IgG2 monoclonal antibody composed of the IgG2a chain of a mouse anti-EpCAM antibody and the IgG2b chain of a rat anti-CD3 antibody. Its targets are epithelial cell adhesion molecule (EpCAM) and the T-cell surface antigen CD3. By simultaneously binding to EpCAM (a target highly expressed in epithelial-derived tumors) on tumor cells and CD3 on T cells, and through its Fc segment binding to Fcγ receptors on the surface of accessory cells such as macrophages and natural killer (NK) cells, the antibody forms a tri-cellular complex among tumor cells, T cells, and accessory cells. This complex synergistically activates multiple immune effects including T cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), ultimately leading to the effective elimination of EpCAM-positive tumor cells. Its main clinical application is the intraperitoneal perfusion treatment of malignant ascites caused by EpCAM-positive epithelial-derived tumors. As a research-grade equivalent product, it can be used for studies on the mechanisms related to tumor immunotherapy.